Profilo
David A.
Bullough is the founder of Thirona Bio, Inc. He is currently holding two jobs, one as Vice President-Pre-Clinical Development at Metabasis Therapeutics, Inc. since 1997 and the other as Chief Scientific Officer at Lipidio Pharmaceuticals, Inc. He holds a doctorate degree from the University of Cambridge.
Posizioni attive di David A. Bullough
Società | Posizione | Inizio |
---|---|---|
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 14/09/2009 |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | Founder | - |
Formazione di David A. Bullough
University of Cambridge | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Health Technology |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | Health Technology |
Thirona Bio, Inc.
Thirona Bio, Inc. Pharmaceuticals: MajorHealth Technology Thirona Bio, Inc. is an American biopharmaceutical company that focuses on developing drugs for fibrotic diseases. Thirona Bio is based in an undisclosed location. The private company's target indications include scleroderma, keloid scars, and certain cancers where there are no effective therapies. The company's unique approach uses a potent, topically applied drug to inhibit TGF-? "locally," minimizing the potential risk of systemic toxicity. The company was founded by John Gordon Foulkes, Jay Edward Birnbaum, K. George Mooney, and David A. Bullough, with John Gordon Foulkes serving as the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- David A. Bullough